Allergan, Inc. announced that the United States Food and Drug Administration has approved OZURDEX 0.7 mg for the treatment of non-infectious ocular inflammation, or uveitis, affecting the posterior segment of the eye.
Galapagos NV announced that it has started a Phase 2 clinical study for the company’s flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis.
AstraZeneca’s oral syk inhibitor, fostamatinib, in-licensed from Rigel Pharmaceuticals, Inc., significantly improved outcomes of patients with rheumatoid arthritis who responded inadequately to methotrexate, according to recently published phase 2 study data.
Movetis NV announces that it has started a phase 3 clinical trial with prucalopride in male patients with chronic constipation. Positive results from this clinical trial should allow Movetis to apply for expansion of the current label of Resolor.
Depomed received a $500,000 payment from its partner Covidien PLC, which has started human testing of an extended-release painkiller using its technology.
XOMA Ltd. announced that patient enrollment was recently completed for the company's Phase 2a trial of XOMA 052 in patients with Type 2 diabetes. XOMA 052 is a therapeutic antibody candidate that inhibits the inflammatory cytokine interleukin-1 beta.
AMSBIO has announced Solu BL21 Competent E. coli, a significantly improved BL21 host strain for soluble mammalian protein expression.
The AB SCIEX TripleTOF 5600 System is a fast and sensitive high-resolution mass spectrometer for high-performance qualitative and quantitative analysis.
Microsonic Systems has announced that its HENDRIX SM100 now serves four key applications: Compound solubilization, Sample thawing, Microplate mixing, and Magnetic particles/cells suspension.
Within the next four years GATC Biotech plans to analyse 100,000 human genomes in particular for the pharmaceutical and diagnostic industry as well as for academic research.
Walgreen Co., the largest drugstore chain in the U.S., said its net income rose 8 percent in the fiscal fourth quarter on higher prescription drug sales.
Chelsea Therapeutics International, Ltd. has initiated enrollment in a Phase 2 trial designed to compare the efficacy and tolerability of CH-4051 against methotrexate in patients with rheumatoid arthritis who are experiencing an inadequate response to methotrexate.
Cytheris SA announced that it has begun enrolling patients in a Phase 2 clinical trial evaluating the effect of repeated cycles of CYT107 in HIV-1 infected patients classified as immunological non-responders after at least 24 months of HAART.
A new analysis suggests that broader statin use among adult patients may be a cost-effective way to prevent heart attack and stroke.
Mayo Clinic researchers and their international colleagues have discovered genetic variants that lead to severe arthritis for a subset of women when taking aromatase inhibitors to treat their breast cancer.